Open AccessMorphological Features of Minimal Change Disease and Focal Segmental Glomerulosclerosis Using Repeat Biopsy and Parietal Epithelial Cell Marker
Author(s) -
Suzuki Tomo,
Kohatsu Kaori,
Han Wei,
Watanabe Shiika,
Yahagi Koichi,
Nakata Mayumi,
Ueno Toshiharu,
Ichikawa Daisuke,
Imai Naohiko,
Shirai Sayuri,
Koike Junki,
Shibagaki Yugo
Publication year - 2020
Publication title -
kidney diseases
Language(s) - English
Resource type - Journals
eISSN - 2296-9357
pISSN - 2296-9381
DOI - 10.1159/000505125
Subject(s) - research article
Minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS) are representative podocyte diseases. The clinical cause of MCD and FSGS has not been clearly elucidated yet. However, it is important to distinguish MCD and FSGS because their prognoses and responses to treatment are quite different. Objective: This study aimed to examine whether parietal epithelial cell (PEC) marker and repeat biopsy are useful for diagnosing primary FSGS. Methods: Clinicopathological features of 17 patients with the nephrotic syndrome, who underwent kidney biopsy ≥2 times from 1975 to 2017, and had MCD or FSGS were analyzed using PAX8. We defined patients with PAX8+ cells as PAX8+ and the remainder as PAX8– patients. Three cases of sample insufficiency and 1 non-steroid-resistant or frequently relapsing case indicated for repeat biopsy were excluded. Results: Among the 13 patients studied, 4 were PAX8+ and 9 were PAX8– (median age: 41 and 46 years, respectively, at first biopsy). PAX8+ and PAX8– patients showed no significant differences in clinical data and histological diagnosis except for a significant difference in histological diagnosis at the second biopsy. The number of PAX8+ patients increased to 6. Unlike the first biopsy results, FSGS was present in 5 of 6 (83.3%) PAX8+ patients; MCD occurred in all 7 (100%) PAX8– patients. Three of 6 (50.0%) PAX8+ patients undergoing repeat biopsy were steroid resistant; no (0%) PAX8– patient was steroid resistant. All cases of final FSGS diagnosis were PAX8+ at the first or second biopsy. Only 1 PAX8+ MCD patient was steroid resistant. All PAX8– MCD patients were frequently relapsing. Conclusions: More PAX8+ patients were diagnosed with FSGS than PAX8– patients. Clinical presentation of MCD in PAX8– patients was frequently relapsing. PEC marker staining in patients with the nephrotic syndrome, e.g., MCD, may help to diagnose FSGS.